Movetis Seeking €112.5M: Is End to Europe's IPO Drought Near?
BioWorld International Correspondent
Movetis NV is testing the mettle of European life sciences investors with the sector's first sizeable initial public offering since the first quarter of 2008.
With a European product launch imminent, the company offers a far less risky proposition than most, however.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter